ETH Zurich Creates Light-Controlled Molecular Switch to Destroy Cancer Cell Survival Receptors

Breakthrough in Cancer Treatment Strategy

Some cancer cells evade treatment by entering a dormant state triggered by stress hormones. ETH Zurich scientists have created a light-controlled molecular switch that selectively destroys the receptors responsible for this survival mode. This discovery represents a significant advancement in addressing one of oncology's most challenging problems—the ability of cancer cells to escape standard therapies.

The Dormancy Problem

Cancer dormancy is a well-known mechanism by which malignant cells survive chemotherapy and other treatments. When exposed to stress—whether from chemotherapy, radiation, or other therapeutic interventions—some cancer cells enter a quiescent state, dramatically reducing their metabolic activity and making them invisible to treatment strategies designed to target rapidly dividing cells. This dormancy has been a major barrier to achieving durable remission in many cancer types.

The Molecular Switch Solution

The ETH Zurich team's approach uses light to control the destruction of specific receptors that mediate this survival response. By harnessing photochemistry—the interaction of light with molecules—the researchers engineered a system that can be precisely activated in time and space. This precision is critical, as it minimizes off-target effects and allows for targeted intervention in tumor tissue while sparing healthy cells.

Path Forward

This light-activated strategy opens new therapeutic avenues. Rather than attempting to kill dormant cells directly (which is inherently difficult), this approach blocks their ability to survive in the dormant state, potentially forcing them back into an active state where conventional therapies become effective. The combination of dormancy prevention with standard oncology treatments could significantly improve patient outcomes across multiple cancer types.